Defining the immunogram of breast cancer: a focus on clinical trials

Paolo Tarantino, Giuseppe Curigliano

Research output: Contribution to journalEditorialpeer-review


In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome. Enriching future trials through these biomarkers could help identifying the population of responders, realizing what has been called precision immunotherapy.

Original languageEnglish
Pages (from-to)383-385
Number of pages3
JournalExpert Opinion on Biological Therapy
Issue number5
Publication statusPublished - May 4 2019


  • Breast cancer
  • clinical trials
  • immunogram
  • immunotherapy
  • response biomarker

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Defining the immunogram of breast cancer: a focus on clinical trials'. Together they form a unique fingerprint.

Cite this